Curriculum Taxonomy & Thematic Focus
The Annual Colloquium on Precision Oncology & Next-Gen Therapeutics convenes multi-disciplinary investigators to bridge fundamental molecular discoveries with prospective clinical trial endpoints. The scientific scope encompasses four foundational tracks spanning high-throughput genomic mapping, targeted cellular re-engineering, minimal disease monitoring, and synthetic lethal resistance biology.
PrecisionOnco 2027 prioritizes translational data with direct clinical utility. Accepted proffered papers must present verifiable empirical methodologies—encompassing human tissue biobanking, prospective patient cohort analysis, validated murine/organoid avatars, or Phase I–III clinical trial interim readouts.
Multi-Omics Profiling, Neoantigens & Spatial Biology
Investigating high-resolution characterization of intratumoral heterogeneity, computational prediction of immunogenic private neoantigens, and the spatial orchestration of cellular phenotypes within refractory tumor microenvironments.
Spatial Transcriptomics & Proteomics
- Sub-cellular resolution imaging of invasive tumor margins
- Spatial mapping of tertiary lymphoid structures (TLS)
- Quantifying spatial checkpoint expression (PD-L1/LAG-3/TIGIT)
- Multiplexed ion beam imaging and digital spatial profiling
Neoepitope Discovery & HLA Presentation
- Mass spectrometry-based immunopeptidome profiling
- AI and structural modeling of TCR-pMHC binding affinity
- Shared neoantigen targets in KRAS, TP53, and PIK3CA
- Personalized mRNA and long-peptide vaccine formulation
Epigenomic & Multi-Omic Integration
- Single-cell ATAC-seq and chromatin accessibility profiling
- Epigenetic drivers of de-differentiation and plasticity
- Multi-modal data alignment for patient stratifications
- Standardization of clinical bioinformatics pipelines
Cellular Therapies & Synthetic Immune Engineering
Advancing engineered cell architecture beyond classical autologous paradigms—focusing on gene-edited allogeneic platforms, armored chimeric receptors, dual-targeting constructs, and overcoming structural stromal barriers in solid tumors.
Next-Generation CAR-T & TCR-T
- Multiplex base-editing and CRISPR-Cas knockouts to prevent graft-versus-host disease (GvHD)
- Dual-specific (tandem/bicistronic) CAR targeting strategies
- Armored constructs secreting localized IL-7, IL-15, or TGF-beta traps
- TCR-engineered T cells directed against intracellular driver mutations
Allogeneic & Alternative Effectors
- Off-the-shelf induced pluripotent stem cell (iPSC)-derived NK cells
- Gamma-delta (γδ) T cells and invariant NKT platform architectures
- Engineered macrophage therapies targeting fibrotic tumor stroma
- Persistence optimization and functional exhaustion mitigation
Clinical Toxicity & In Vivo Kinetics
- Biomarkers predicting severe CRS and neurotoxicity (ICANS)
- Synthetic logic-gated "kill-switch" receptors for safety control
- Non-invasive cellular tracking and expansion kinetics in vivo
- Decentralized and automated point-of-care cell biomanufacturing
Liquid Biopsy, ctDNA & Minimal Residual Disease (MRD)
Validating circulating biomarkers for early molecular recurrence detection, therapy de-escalation, non-invasive resistance tracking, and fragmentomic multi-cancer screening.
Minimal Residual Disease (MRD)
- Tumor-informed vs tumor-agnostic assays in post-surgical cohorts
- ctDNA clearance as an early surrogate endpoint for RFS and OS
- Interventional trial designs driven by molecular recurrence
- Overcoming false negatives in low-shedding malignancies
Beyond Base Substitutions: Fragmentomics
- Circulating cell-free DNA methylation profiling
- Fragment size distribution and nucleosome footprinting
- Circulating extracellular vesicles (EVs) and exosomal RNA cargo
- Multi-analyte blood-based cancer screening methodologies
Serial Resistance Monitoring
- Tracking clonal evolution and subclonal emergence on therapy
- Plasma-first genotyping for immediate second-line selection
- Analytical limits of detection (LOD) and CLIA/CAP harmonization
- Cross-platform reproducibility between digital PCR and hybrid NGS
Acquired Resistance & Synergistic Combination Regimens
Deciphering mechanisms of therapeutic escape across small-molecule kinase inhibitors, antibody-drug conjugates (ADCs), and immune checkpoint modulators to devise rational multi-target intervention frameworks.
Antibody-Drug Conjugates (ADCs)
- Mechanisms of ADC internalization resistance and payload efflux
- Novel cleavable linkers and next-generation topoisomerase I payloads
- Bystander killing dynamics in low-antigen-density malignancies
- Sequencing ADCs with systemic immune checkpoint blockade
Targeting the RAS/MAPK & PI3K Cascades
- Overcoming on-target secondary mutations in KRAS G12C/D/V
- Vertical pathway suppression and bypass receptor activation (MET, HER3)
- PROTACs and molecular glues for previously undruggable targets
- Synthetic lethality screens in DNA damage repair (DDR) deficiencies
Immunotherapy Refractoriness
- Antigen presentation loss (B2M, HLA class I down-regulation)
- Metabolic immunosuppression (adenosine axis, IDO1, lactate accumulation)
- Novel innate immune agonists (STING, TLR7/8) to reprogram cold tumors
- Investigator-initiated Phase I/II combination trial results
- Empirical Translational Trials: Prospective or retrospective patient cohorts featuring molecular biomarkers or clinical response correlations.
- Pre-Clinical In Vivo Verification: Studies utilizing patient-derived xenografts (PDX), organoids, or syngeneic murine models to test therapeutic mechanisms.
- Novel Assay Validation: Methodological papers establishing limits of detection, analytical precision, and clinical concordance for genomic or liquid biopsy assays.
- Phase I/II Clinical Trials: Dose escalation, biomarker-driven expansion cohorts, pharmacokinetics, and safety/efficacy readouts.
- Purely In Silico Mining: Unvalidated bioinformatics analyses of public datasets (e.g., TCGA, GEO) without wet-lab or clinical cohort validation.
- Unverified Single Case Reports: Isolated clinical anecdotes that lack molecular pathology mechanisms or sequencing verification.
- Non-Peer-Reviewed Commercial Marketing: Promotional papers lacking detailed experimental materials and methods or independent verification.
- Alternative Medicine Formulations: Submissions evaluating uncharacterized plant extracts or non-standardized chemical preparations.
Submit a Proffered Abstract to the Scientific Committee
Abstract submissions are assigned to relevant track subcommittees for double-blind peer review. Accepted abstracts are scheduled for 15-minute oral podium talks or moderated poster defense tracks, and indexed in the official colloquium proceedings compendium.